IDVYNSOTM (doravirine/islatravir) is a fixed-dose combination
of 100 mg doravirine and 0.25 mg islatravir with multiple mechanisms of action
IDVYNSO components and mechanisms of action
IDVYNSO combines islatravir, a potent next-generation NRTI with multiple mechanisms of action, including translocation inhibition, with doravirine, an NNRTI with an established efficacy and safety profile.
IDVYNSO mechanisms of action and components Diagram showing that IDVYNSO combines two HIV-1 reverse transcriptase inhibitors: doravirine and islatravir. The left side explains that doravirine is a pyridinone non-nucleoside reverse transcriptase inhibitor, or NNRTI, and that it blocks HIV-1 replication by non-competitive inhibition of reverse transcriptase. The right side explains that islatravir is a next-generation deoxyadenosine nucleoside reverse transcriptase inhibitor, or NRTI, that is phosphorylated inside cells to its active form, islatravir-triphosphate. The diagram shows islatravir-triphosphate inhibiting reverse transcriptase in two ways: translocation reverse transcription, where it blocks movement of the enzyme along the viral DNA strand, causing immediate chain termination, and by inducing structural changes in viral DNA that prevent further nucleotide incorporation, causing delayed chain termination. IDVYNSO mechanisms of action and components Diagram showing that IDVYNSO combines two HIV-1 reverse transcriptase inhibitors: doravirine and islatravir. The left side explains that doravirine is a pyridinone non-nucleoside reverse transcriptase inhibitor, or NNRTI, and that it blocks HIV-1 replication by non-competitive inhibition of reverse transcriptase. The right side explains that islatravir is a next-generation deoxyadenosine nucleoside reverse transcriptase inhibitor, or NRTI, that is phosphorylated inside cells to its active form, islatravir-triphosphate. The diagram shows islatravir-triphosphate inhibiting reverse transcriptase in two ways: translocation reverse transcription, where it blocks movement of the enzyme along the viral DNA strand, causing immediate chain termination, and by inducing structural changes in viral DNA that prevent further nucleotide incorporation, causing delayed chain termination. 
